Biocompatible ocular implants
First Claim
Patent Images
1. A method for treating an eye condition which comprises:
- preparing a non-biodegradable physiologically acceptable implant comprising a physiologically active therapeutic agent and a membrane layer for controlling the diffusion of said therapeutic agent from said polymer;
introducing said implant extrinsic to the vitreous such that the membrane layer is positioned intermediate to said polymer and said site of said eye condition, and is incapable of migration from an implantation site, wherein said site comprises the suprachoroidal space and a surgically induced avascular region of the choroid, permitting diffusion of a physiologically active agent from said implant into the vitreous, and in proximity to said eye condition;
wherein said therapeutic agent is maintained at an effective dosage for said eye condition at the site of said eye condition for an extended period of time.
8 Assignments
0 Petitions
Accused Products
Abstract
Implants comprising active agents are employed for introduction into a suprachoroidal space or an avascular region of an eye for therapeutic purposes. The administration of drugs is controlled and maintained for long periods of time, while ensuring the substantial absence of significant levels outside the site of administration.
-
Citations
5 Claims
-
1. A method for treating an eye condition which comprises:
-
preparing a non-biodegradable physiologically acceptable implant comprising a physiologically active therapeutic agent and a membrane layer for controlling the diffusion of said therapeutic agent from said polymer; introducing said implant extrinsic to the vitreous such that the membrane layer is positioned intermediate to said polymer and said site of said eye condition, and is incapable of migration from an implantation site, wherein said site comprises the suprachoroidal space and a surgically induced avascular region of the choroid, permitting diffusion of a physiologically active agent from said implant into the vitreous, and in proximity to said eye condition; wherein said therapeutic agent is maintained at an effective dosage for said eye condition at the site of said eye condition for an extended period of time. - View Dependent Claims (2, 3, 4, 5)
-
Specification